Progestin-only contraception and thromboembolism: A systematic review



      Women with medical conditions associated with increased risk for thrombosis generally should not use estrogen-containing contraceptives; however, less is known about progestin-only contraceptives (POCs) and thrombosis risk.


      The objective was to identify evidence regarding the risk of venous thromboembolism (VTE) or arterial thromboembolism [stroke or acute myocardial infarction (AMI)] among women using POCs.


      We searched the PubMed database for all articles published from database inception through January 2016 for studies examining thrombosis among women using POCs. We included studies which examined women with medical conditions associated with thrombosis risk, as well as studies of women in the general population (either without these conditions or who were not specified to have these conditions). Hormonal contraceptives of interest included progestin-only pills (POPs), injectables, implants and levonorgestrel-releasing intrauterine devices (LNG-IUDs). Outcomes of interest included VTE, stroke and AMI.


      There were 26 articles of good to poor quality that met inclusion criteria; 9 studies examined women with medical conditions and 20 examined women in the general population. Two studies found that, among smokers and women with certain thrombogenic mutations, use of depot medroxyprogesterone acetate (DMPA) had elevated odds of VTE compared with nonsmokers or those without mutations, although confidence intervals were wide and overlapped with odds among nonusers. One study found that, among women with previous VTE, use of POCs (including DMPA) was associated with a nonsignificant increased odds of recurrent VTE (all of which were among DMPA users); two other studies that examined POCs other than DMPA did not observe an association with recurrent VTE. Two studies found that use of DMPA among healthy women was also associated with increased odds of VTE. Two studies found that use of POCs for therapeutic indications was associated with increased odds of VTE. Studies did not find increased odds of VTE with POPs for contraceptive purposes, implants or LNG-IUDs nor were there increased odds of stroke or AMI with any POCs.


      The majority of evidence identified by this systematic review did not suggest an increase in odds for venous or arterial events with use of most POCs. Limited evidence suggested increased odds of VTE with use of injectables (three studies) and use of POCs for therapeutic indications (two studies, one with POCs unspecified and the other with POPs). Any increase in risk likely translates to a small increase in absolute numbers of thrombotic events at the population level.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Stegeman B.H.
        • de Bastos M.
        • Rosendaal F.R.
        • van Hylckama V.A.
        • Helmerhorst F.M.
        • Stijnen T.
        • et al.
        Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.
        BMJ. 2013; 347: f5298
        • Peragallo Urrutia R.
        • Coeytaux R.R.
        • McBroom A.J.
        • Gierisch J.M.
        • Havrilesky L.J.
        • Moorman P.G.
        • et al.
        Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis.
        Obstet Gynecol. 2013; 122: 380-389
        • Lidegaard O.
        • Lokkegaard E.
        • Jensen A.
        • Skovlund C.W.
        • Keiding N.
        Thrombotic stroke and myocardial infarction with hormonal contraception.
        New Engl J Med. 2012; 366: 2257-2266
        • Tchaikovski S.N.
        • Rosing J.
        Mechanisms of estrogen-induced venous thromboembolism.
        Thromb Res. 2010; 126: 5-11
        • Bergendal A.
        • Persson I.
        • Odeberg J.
        • Sundstrom A.
        • Holmstrom M.
        • Schulman S.
        • et al.
        Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes.
        Obstet Gynecol. 2014; 124: 600-609
        • van Hylckama V.A.
        • Helmerhorst F.M.
        • Rosendaal F.R.
        The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
        Arterioscler Thromb Vasc Biol. 2010; 30: 2297-2300
        • Centers for Disease Control and Prevention
        U.S. Medical Eligibility Criteria for Contraceptive Use, 2010.
        MMWR Recomm Rep. 2010; 59: 1-86
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • Group P.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339: b2535
        • Harris R.P.
        • Helfand M.
        • Woolf S.H.
        • Lohr K.N.
        • Mulrow C.D.
        • Teutsch S.M.
        • et al.
        Current methods of the US Preventive Services Task Force: a review of the process.
        Am J Prev Med. 2001; 20: 21-35
      1. Contraception. 1998; 57: 315-324
        • Barsoum M.K.
        • Heit J.A.
        • Ashrani A.A.
        • Leibson C.L.
        • Petterson T.M.
        • Bailey K.R.
        Is progestin an independent risk factor for incident venous thromboembolism? A population-based case–control study.
        Thromb Res. 2010; 126: 373-378
        • Conard J.
        • Plu-Bureau G.
        • Bahi N.
        • Horellou M.H.
        • Pelissier C.
        • Thalabard J.C.
        Progestogen-only contraception in women at high risk of venous thromboembolism.
        Contraception. 2004; 70: 437-441
        • Dunn N.
        • Thorogood M.
        • Faragher B.
        • de Caestecker L.
        • MacDonald T.M.
        • McCollum C.
        • et al.
        Oral contraceptives and myocardial infarction: results of the MICA case–control study.
        BMJ. 1999; 318: 1579-1583
        • Heinemann L.A.
        • Assmann A.
        • DoMinh T.
        • Garbe E.
        Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women.
        Eur J Contracept Reprod Health Care. 1999; 4: 67-73
        • Lidegaard O.
        Oral contraception and risk of a cerebral thromboembolic attack: results of a case–control study.
        BMJ. 1993; 306: 956-963
        • Lidegaard O.
        • Edstrom B.
        • Kreiner S.
        Oral contraceptives and venous thromboembolism. A case–control study.
        Contraception. 1998; 57: 291-301
        • Lidegaard O.
        • Edstrom B.
        • Kreiner S.
        Oral contraceptives and venous thromboembolism: a five-year national case–control study.
        Contraception. 2002; 65: 187-196
        • Lidegaard O.
        • Kreiner S.
        Contraceptives and cerebral thrombosis: a five-year national case–control study.
        Contraception. 2002; 65: 197-205
        • Lidegaard O.
        • Lokkegaard E.
        • Svendsen A.L.
        • Agger C.
        Hormonal contraception and risk of venous thromboembolism: national follow-up study.
        BMJ. 2009; 339: b2890
        • Lidegaard O.
        • Nielsen L.H.
        • Skovlund C.W.
        • Lokkegaard E.
        Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10.
        BMJ. 2012; 344e2990
        • Lidegaard O.
        • Nielsen L.H.
        • Skovlund C.W.
        • Skjeldestad F.E.
        • Lokkegaard E.
        Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9.
        BMJ. 2011; 343: d6423
        • Mintz G.
        • Gutierrez G.
        • Deleze M.
        • Rodriguez E.
        Contraception with progestagens in systemic lupus erythematosus.
        Contraception. 1984; 30: 29-38
        • Petitti D.B.
        • Siscovick D.S.
        • Sidney S.
        • Schwartz S.M.
        • Quesenberry C.P.
        • Psaty B.M.
        • et al.
        Norplant implants and cardiovascular disease.
        Contraception. 1998; 57: 361-362
        • Poulter N.R.
        • Chang C.L.
        • Farley T.M.
        • Meirik O.
        Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications.
        Lancet. 1999; 354: 1610
        • Vaillant-Roussel H.
        • Ouchchane L.
        • Dauphin C.
        • Philippe P.
        • Ruivard M.
        Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives.
        Contraception. 2011; 84: e23-e30
        • Vasilakis C.
        • Jick H.
        • del Mar Melero-Montes M.
        Risk of idiopathic venous thromboembolism in users of progestagens alone.
        Lancet. 1999; 354: 1610-1611
        • Le Moigne E.
        • Tromeur C.
        • Delluc A.
        • Gouillou M.
        • Alavi Z.
        • Lacut K.
        • et al.
        Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study.
        Haematologica. 2016; 101: e12-e14
        • Bergendal A.
        • Bremme K.
        • Hedenmalm K.
        • Larfars G.
        • Odeberg J.
        • Persson I.
        • et al.
        Risk factors for venous thromboembolism in pre- and postmenopausal women.
        Thromb Res. 2012; 130: 596-601
        • Rosenberg L.
        • Palmer J.R.
        • Rao R.S.
        • Shapiro S.
        Low-dose oral contraceptive use and the risk of myocardial infarction.
        Arch Intern Med. 2001; 161: 1065-1070
        • Thorogood M.
        • Mann J.
        • Murphy M.
        • Vessey M.
        Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case–control study.
        Brit J Obstet Gynaecol. 1991; 98: 1245-1253
        • Tzourio C.
        • Tehindrazanarivelo A.
        • Iglesias S.
        • Alperovitch A.
        • Chedru F.
        • d'Anglejan-Chatillon J.
        • et al.
        Case–control study of migraine and risk of ischaemic stroke in young women.
        BMJ. 1995; 310: 830-833
        • Christiansen S.C.
        • Lijfering W.M.
        • Helmerhorst F.M.
        • Rosendaal F.R.
        • Cannegieter S.C.
        Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event.
        J Thromb Haemost. 2010; 8: 2159-2168
        • Bergendal A.
        • Odlind V.
        • Persson I.
        • Kieler H.
        Limited knowledge on progestogen-only contraception and risk of venous thromboembolism.
        Acta Obstet Gynecol Scand. 2009; 88: 261-266
        • Mantha S.
        • Karp R.
        • Raghavan V.
        • Terrin N.
        • Bauer K.A.
        • Zwicker J.I.
        Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis.
        BMJ. 2012; 345e4944
        • Chakhtoura Z.
        • Canonico M.
        • Gompel A.
        • Thalabard J.C.
        • Scarabin P.Y.
        • Plu-Bureau G.
        Progestogen-only contraceptives and the risk of stroke: a meta-analysis.
        Stroke. 2009; 40: 1059-1062
        • Chakhtoura Z.
        • Canonico M.
        • Gompel A.
        • Scarabin P.Y.
        • Plu-Bureau G.
        Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis.
        J Clin Endocrinol Metab. 2011; 96: 1169-1174
        • Alhenc-Gelas M.
        • Plu-Bureau G.
        • Guillonneau S.
        • Kirzin J.M.
        • Aiach M.
        • Ochat N.
        • et al.
        Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.
        J Thromb Haemost. 2004; 2: 1594-1600
        • Kuhl H.
        Effects of progestogens on haemostasis.
        Maturitas. 1996; 24: 1-19
        • Vieira C.S.
        • Ferriani R.A.
        • Garcia A.A.
        • Pintao M.C.
        • Azevedo G.D.
        • Gomes M.K.
        • et al.
        Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
        Hum Reprod. 2007; 22: 2196-2201
        • Jackson E.
        • Curtis K.M.
        • Gaffield M.E.
        Risk of venous thromboembolism during the postpartum period: a systematic review.
        Obstet Gynecol. 2011; 117: 691-703
        • Blanco-Molina M.A.
        • Lozano M.
        • Cano A.
        • Cristobal I.
        • Pallardo L.P.
        • Lete I.
        Progestin-only contraception and venous thromboembolism.
        Thromb Res. 2012; 129: e257-e262
        • Lijfering W.M.
        • Rosendaal F.R.
        • Cannegieter S.C.
        Risk factors for venous thrombosis - current understanding from an epidemiological point of view.
        Brit J Haematol. 2010; 149: 824-833
        • Ageno W.
        • Becattini C.
        • Brighton T.
        • Selby R.
        • Kamphuisen P.W.
        Cardiovascular risk factors and venous thromboembolism: a meta-analysis.
        Circulation. 2008; 117: 93-102
        • Roach R.E.
        • Lijfering W.M.
        • Helmerhorst F.M.
        • Cannegieter S.C.
        • Rosendaal F.R.
        • van Hylckama Vlieg A.
        The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
        J Thromb Haemost. 2013; 11: 124-131
      2. J Clin Epidemiol. 1995; 48: 1513-1547
        • Spitzer W.O.
        • Lewis M.A.
        • Heinemann L.A.
        • Thorogood M.
        • MacRae K.D.
        Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case–control study. Transnational research group on oral contraceptives and the health of young women.
        BMJ. 1996; 312: 83-88
        • Lewis D.M.
        • Assmann A.
        • Heinemann L.
        • Spitzer W.O.
        Interim review of the transnational case–control study of oral contraceptives and health: approved protocol revisions through September 1995.
        Pharmacoepidemiol Drug Saf. 1996; 5: 43-51
        • Schwartz S.M.
        • Siscovick D.S.
        • Longstreth Jr., W.T.
        • Psaty B.M.
        • Beverly R.K.
        • Raghunathan T.E.
        • et al.
        Use of low-dose oral contraceptives and stroke in young women.
        Ann Intern Med. 1997; 127: 596-603
        • Petitti D.B.
        • Sidney S.
        • Bernstein A.
        • Wolf S.
        • Quesenberry C.
        • Ziel H.K.
        Stroke in users of low-dose oral contraceptives.
        N Engl J Med. 1996; 335: 8-15
        • Sidney S.
        • Petitti D.B.
        • Quesenberry Jr., C.P.
        • Klatsky A.L.
        • Ziel H.K.
        • Wolf S.
        Myocardial infarction in users of low-dose oral contraceptives.
        Obstet Gynecol. 1996; 88: 939-944
        • Jick H.
        • Jick S.S.
        • Gurewich V.
        • Myers M.W.
        • Vasilakis C.
        Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
        Lancet. 1995; 346: 1589-1593
        • van Hylckama Vlieg A.
        • Helmerhorst F.M.
        • Vandenbroucke J.P.
        • Doggen C.J.
        • Rosendaal F.R.
        The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case–control study.
        BMJ. 2009; 339: b2921